Therapeutic area intelligence for NAFLD and Dermatology with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Companies: 1

Companies

AbbVie →

Assets

Guselkumab →

Recent signals(1)

ClinicalAugust 3, 2026

Study on Guselkumab Therapy's Impact on NAFLD in PsA Patients

The study investigates the effects of Guselkumab on disease severity in PsA patients with NAFLD.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Psoriatic Arthritis →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.